Glycopyrronium Bromide

Glycopyrronium Bromide 化学特性,用途語,生産方法

• 説明

  Glycopyrronium bromide or NVA 237 is a once-daily inhaled antimuscarinic bronchodilator newly approved by the European Commission for use in stable COPD. It is characterized by a quaternary ammonium structure, which reduces its oral bioavailability and, consequently, the systematic effects of any swallowed portion of the drug. Animal studies suggest that there are fewer cardiovascular effects compared to tiotropium because of the higher affinity to M3 versus M2 muscarinic receptors. Human studies showed fast onset of action, sustained bronchodilatation for 24 h, reduced dynamic hyperinflation of the lungs, and improved exercise tolerance. Glycopyrronium bromide in COPD airways clinical trial series (GLOW1–3) are the major clinical trials studying the efficacy and safety of glycopyrronium[1].

• 化学的特性

  White or almost white, crystalline powder.

• 使用

  erythro-Glycopyrronium Bromide is used in preparation of diester containing compounds for treating hyperhidrosis.

• 適応症

  Glycopyrronium bromide is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions, and to block cardiac vagal inhibitory reflexes during induction of anaesthesia and intubation when indicated. Glycopyrronium bromide may be used intraoperatively to counteract drug-induced or vagal traction reflexes with the associated arrhythmias. Glycopyrronium bromide protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarising muscle relaxants.

Glycopyrronium Bromide 生産企業

Global(82)Suppliers

51186-83-5, Glycopyrronium Bromide キーワード